

Partnering to defeat cancer



Tuesday 3 July

The Science Room, Royal Society of Chemistry
Burlington House, London W1J 0BA

Agenda

Speaker

07.30	Registration and buffet breakfast	
08.00	Welcome & breakfast briefing	Professor Paul Workman, Chief Executive, ICR
08.25	ICR quick-fire showcase	Professor Kevin Harrington Professor Paul Jeffreys Dr Chris Bakal Dr Alessandro Vannini
09.05	Coffee break and networking	
09.35	Working with the ICR – Astex Pharmaceuticals	Dr Tom Heightman Head of Chemistry
09.55	ICR capabilities overview	Dr Angela Kukula, Director of Enterprise, ICR
10.10	The importance of the business/academic relationship	Dr Tony Jones CEO One Nucleus
10.25	Closing remarks and thanks	Dr Angela Kukula, ICR
10.30	Event finishes and networking opportunity	

Professor Paul Workman



Professor Paul Workman FRS FMedSci is Chief Executive and President of The Institute of Cancer Research (ICR), London, and Harrap Professor of Pharmacology and Therapeutics. For 19 years, he was Director of the Cancer Research UK Cancer Therapeutics Unit at the ICR – the world's largest non-profit cancer drug discovery group.

Paul has been responsible for more than 20 cancer drugs entering clinical trial. He is renowned for his innovative, successful research, having led several successful drug discovery teams in academia and in the biotechnology and pharmaceutical industry.

Paul continues to run his own lab, carrying out a significant amount of research at a pioneering level, ranging across a number of techniques,

tumour types and including molecular targets in oesophageal cancer.

Before joining the ICR, Paul spent 4 years leading cancer research at AstraZeneca, having worked at Glasgow, Stanford and Cambridge Universities. He co-founded Piramed Pharma (acquired by Roche) and Chroma Therapeutics.

As CEO and President of the ICR, Paul guides strategic developments in basic, translational and clinical cancer research. He talks, writes and blogs about cancer and the drug discovery ecosystem.

Paul has won numerous awards and fellowships including being elected as a Fellow of the Royal Society in 2016. He was named in the Evening Standard's Progress 1000 list of the most influential people in London.

Dr Angela Kukula



Dr Angela Kukula is Director of Enterprise at The Institute of Cancer Research in London. Her team of 16 in the Enterprise Unit manage all intellectual property and commercial issues at the ICR including managing collaborations with industry, negotiating clinical trial agreements, patenting, licensing and the formation of spin-out companies.

The Enterprise Unit generates more than £10m per annum in collaboration income and more than £25m per year in invention income – more than any other UK Higher Education Institution.

Angela has a BA in Biochemistry from Oxford University and PhD in Immunology and Genetics from the University of London. She also has an MBA specialising in technology management and an LLM in commercial law. She is the current chair of PraxisAuril - an educational not-for-profit organisation set up to support innovation and commercialisation of public sector and charity research for social and economic impact.

Dr Tom Heightman



Dr Tom Heightman joined Astex in January 2011. Before joining Astex he worked for 10 years at GlaxoSmithKline in Harlow, UK, where he contributed to the discovery of over a dozen preclinical candidates across multiple therapeutic areas; and for three years at the Structural Genomics Consortium in Oxford University, as project manager for the Epigenetics Chemical Probes Consortium.

Tom is a fellow of the Royal Society of Chemistry, having served on the Biological and

Medicinal Chemistry Sector committee and the Chemistry-Biology Interface Division Council, and has authored more than 90 publications and patents.

He received his MA in Chemistry at the University of Oxford in 1993, and his PhD at the ETH Zürich in 1998.

Dr Tony Jones



Dr Tony Jones is the CEO of One Nucleus and oversees the development of the strategic and operational strategy of the company. He leads the stakeholder, member engagement and membership offer evolution to reflect the current external environment and changing needs placed upon members' businesses.

After completing a PhD in Biochemistry, Tony undertook several years of post-doctoral research in oncology, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into Technology Transfer with the MRC and later UCL, at the Wolfson Institute for Biomedical Research.

In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network, promoting London's excellence in healthcare research and delivery. In May 2010 he merged this organisation with ERBI, continuing to assist member companies to develop their businesses.